Lexeo Therapeutics (LXEO) Amortizatization of Intangibles (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Amortizatization of Intangibles of $42000.0 for Q1 2026, down 47.5% on a YoY basis from $80000.0 in Q1 2025, and down 47.5% sequentially from $80000.0 in Q4 2025.
Lexeo Therapeutics (LXEO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Amortizatization of Intangibles data on file, last reported at $42000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 47.5% year-over-year to $42000.0; the trailing twelve-month figure through Mar 2026 stood at $282000.0 (up 1466.67% YoY), and the FY2025 full-year result was $320000.0, up 1291.3% from the prior year.
- Amortizatization of Intangibles declined to $42000.0 in Q1 2026, from $80000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $90000.0 in Q4 2022 to a low of -$222000.0 in Q4 2024.
- A 5-year average of $55133.3 and a median of $80000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles sank 381.01% in 2024 and soared 136.04% in 2025, its largest moves.
- Tracing LXEO's Amortizatization of Intangibles over 5 years: stood at $90000.0 in 2022, then decreased by 12.22% to $79000.0 in 2023, then slumped by 381.01% to -$222000.0 in 2024, then surged by 136.04% to $80000.0 in 2025, then plunged by 47.5% to $42000.0 in 2026.
- Business Quant data shows LXEO's Amortizatization of Intangibles at $42000.0 in Q1 2026, $80000.0 in Q4 2025, and $80000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Lexeo Therapeutics | 364.11 Mn | 364.11 Mn | - | 42,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,000.00 |
| Mar 31, 2026 | 42,000.00 |
| Dec 31, 2025 | 80,000.00 |
| Dec 31, 2025 | 80,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | -222,000.00 |
| Dec 31, 2024 | -222,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Dec 31, 2023 | 79,000.00 |